{"organizations": [], "uuid": "7c13472a7c491921d1ad792886f0aacb06edc52b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180502.html", "section_title": "Archive News &amp; Video for Wednesday, 02 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-indias-biocon-says-usfda-european/brief-indias-biocon-says-usfda-european-regulator-issue-observations-on-bangalore-plant-idUSL3N1S94GZ", "country": "US", "domain_rank": 408, "title": "BRIEF-India's Biocon Says USFDA, European Regulator Issue Observations On Bangalore Plant", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.75, "site_type": "news", "published": "2018-05-02T23:03:00.000+03:00", "replies_count": 0, "uuid": "7c13472a7c491921d1ad792886f0aacb06edc52b"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-indias-biocon-says-usfda-european/brief-indias-biocon-says-usfda-european-regulator-issue-observations-on-bangalore-plant-idUSL3N1S94GZ", "ord_in_thread": 0, "title": "BRIEF-India's Biocon Says USFDA, European Regulator Issue Observations On Bangalore Plant", "locations": [], "entities": {"persons": [], "locations": [{"name": "usfda", "sentiment": "none"}, {"name": "bangalore", "sentiment": "none"}, {"name": "mumbai", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "biocon ltd", "sentiment": "negative"}, {"name": "european regulator issue observations on bangalore plant", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 2 (Reuters) - Biocon Ltd:\n* SAYS US-FDA COMPLETED PRE-APPROVAL INSPECTION OF STERILE DRUG PRODUCT PLANT IN BANGALORE AND ISSUED A FORM 483 WITH 7 OBSERVATIONS\n* SAYS OBSERVATIONS ARE LARGELY PROCEDURAL AND AIMED AT CONTINUOUS IMPROVEMENT\n* SAYS WILL RESPOND TO THE FDA WITH A CORRECTIVE AND PREVENTIVE ACTION PLAN IN A TIMELY MANNER\n* SAYS HAS ALSO THIS WEEK RECEIVED PRELIMINARY REPORT FROM EUROPEAN REGULATOR POST INSPECTION OF BANGALORE STERILE DRUG PRODUCT PLANT\n* SAYS EUROPEAN REGULATOR LISTS 6 MAJOR OBSERVATIONS WITH NONE CLASSIFIED AS CRITICAL\n* SAYS WILL SUBMIT A CORRECTIVE AND PREVENTIVE ACTION PLAN TO EUROPEAN INSPECTION AGENCY WITHIN STIPULATED TIME PERIOD Source text for Eikon: Further company coverage: (Mumbai newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-02T23:03:00.000+03:00", "crawled": "2018-05-03T12:03:45.005+03:00", "highlightTitle": ""}